Jersey is the largest of the Channel Islands, sitting about 14 miles off the French coast. It’s a British Crown Dependency, which means it’s closely tied to the UK but governs itself and makes its own laws. It’s not part of the United Kingdom. That self-governing status is important here, because it let Jersey build a cannabis licensing framework on its own timeline, separate from Westminster.

The island legalized medical cannabis in 2019, and its government has been open about wanting this industry to grow. Chief Minister Lyndon Farnham has said he wants Jersey to become a “centre of excellence” for medical cannabis, according to WIRED. The timing lines up with Jersey’s agricultural history. Glasshouse crops, tomatoes included, fell by more than 60% between 2011 and 2015 as fuel costs rose and overseas competition got cheaper, per reporting cited by Business of Cannabis. That left a lot of empty, well-built greenhouse space on an island that already knew how to grow things under glass.

Northern Leaf, which operates the largest EU-GMP facility on the island used Its 100,000-square-foot facility in St Lawrence used to grow Jersey tomatoes. Now it grows cannabis strains with names like Pink Gasoline, Moon Beam Gelato, Carbon Fibre, and Gorilla Kush, under automated irrigation, environmental monitoring, and air purification systems.

How Does Jersey’s Medical Cannabis Export System Actually Work?

Here’s the part that’s easy to miss if you only skim the headlines: growing cannabis on Jersey and selling it abroad involves two separate regulatory steps, not one.

First, cultivation. Jersey operates its own commercial licensing regime for medical cannabis producers, a framework that’s existed since 2019, according to MMJDaily. Growers are inspected by the UK’s Medicines and Healthcare products Regulatory Agency, the same body that oversees pharmaceutical standards in Britain. Sarah Clover, a barrister at Kings Chambers who works on Jersey cannabis licensing, told WIRED that this is a major selling point: “Anybody buying from Jersey knows that the stuff coming out of it is absolutely gold standard, because the MHRA says it is.” She also noted how fast the local permitting process moves. “You can make an application for a permit on a Monday and get it on a Tuesday.”

Second, the product itself needs the right pharmaceutical certification to cross borders. Northern Leaf holds a bulk EU-GMP license, which allows it to produce and supply bulk cannabis flower as active pharmaceutical ingredient, often shortened to API, to distributors and packers across the UK and Europe, per MMJDaily. That EU-GMP status is what makes Jersey flower usable in regulated European medicine supply chains in the first place.

But there’s a catch built into Jersey law: producers can only export in bulk, as raw unprocessed flower. They can’t package or finish the product for sale on the island. Northern Leaf has the facilities to do that work in-house. It just isn’t permitted to, under current regulation.

Why Germany and the UK Are Jersey’s Biggest Markets

Northern Leaf exported about £8.4 million worth of medical cannabis in 2025, with the UK and Germany named as its major destinations, according to WIRED. Supporting data gives a clearer picture of why Germany in particular matters so much.

Germany reformed its cannabis law in April 2024, and prescription demand climbed afterward. The country imported more than 200 tonnes of medical cannabis in 2025, nearly triple the 2024 figure, based on German Ministry of Health data reported by International CBC. Northern Leaf supplied 3,590 kg of flower into Germany in 2025, making it the largest single exporter of UK-produced medical cannabis flower into that market, per Business of Cannabis. One analysis found that while Germany’s overall imports dipped slightly in the fourth quarter of 2025, UK and Channel Islands exports into Germany jumped more than elevenfold year on year in that same quarter, a shift that Prohibition Partners analysts credited primarily to Jersey.

The UK side of the business matters too. Estimated UK demand for medical cannabis flower sits somewhere between 20 and 25 tons annually, and Northern Leaf has said it intends to grow its UK supply further in 2026, according to MMJDaily.

None of this happens without logistics working in Jersey’s favor. Company claims cited by Business of Cannabis describe Jersey’s export permit turnaround as among the fastest globally, with shipments able to reach Germany via France in roughly 36 hours. That’s not independently verified, but it fits with Clover’s description of a permitting office that can turn applications around overnight.

Could Local Processing and Packaging Change the Economics?

This live policy question looms over the industry, so we need to be precise about what we know and what remains undecided.

Right now, Jersey law requires producers to export cannabis as bulk raw flower. Someone else, usually in the UK or Germany, does the processing and packaging that turns that flower into a finished medical product. That downstream work is where a lot of the value in a pharmaceutical supply chain typically gets added. A back-of-envelope calculation using WIRED’s reported figures (£8.4 million divided by Northern Leaf’s roughly 8,300 kg share of exports) works out to somewhere around £1 per gram for bulk flower. That’s a rough estimate, not an actual retail or wholesale price, but it shows the basic dynamic: buyers price raw flower as a raw material, while finished, packaged products capture more value elsewhere in the chain.

Northern Leaf wants that to change. The company has the physical infrastructure to process and package product on-island already, according to WIRED, but Jersey law doesn’t currently allow it to sell finished product that way. Clover described the current moment as a “seesaw,” telling WIRED, “It could really take off here. Jersey could be a life sciences hub, not just for cannabis but for all sorts of pharmaceuticals.”

If Jersey does permit local processing and packaging, producers based on the island could plausibly keep more of the margin currently earned by overseas packers, assuming finished-product buyers are willing to source directly from Jersey. If the law stays as it is, CEO Steven Tan has warned that the economics could push the other way. Business of Cannabis reported his view that without a framework supporting downstream value, companies like Northern Leaf may shift toward a distribution model and outsource production to other countries. Energy costs make up roughly 30% of Northern Leaf’s operating expenses, according to the same reporting, and they put pressure on that calculation no matter how the company resolves the processing question. None of this is a prediction. It’s a live decision for Jersey’s government, and the direction it takes will shape whether the island captures more or less of its own supply chain going forward.

What About Public Health and the Recreational Cannabis Debate?

Jersey’s medical cannabis sector hasn’t grown without friction at home. Five private clinics operate on the island, and recent figures suggest about 6% of the population is prescribed cannabis, compared with an estimated 0.4% in Germany and 0.1% in the UK, per Bailiwick Express as cited by WIRED. Jersey’s health minister has said cannabis is a contributory factor in 22% of admissions to the island’s acute mental health ward. Jersey Police have also flagged a rise in “user-dealers,” patients reselling prescribed cannabis, which they say undermines the legal framework. On the other side of the ledger, cannabis-related offenses on the island dropped from 216 in 2016 to just 12 as of July 2026.

Recreational cannabis remains illegal, and a 2024 decriminalization vote failed by a single vote in Jersey’s parliament. A later attempt was withdrawn before debate but is expected to return. Jersey is a signatory to UN drug conventions through the UK, so full recreational legalization likely isn’t entirely the island’s call to make alone. For context, the UK withheld Royal Assent from Bermuda’s 2022 recreational cannabis bill. These tensions sit alongside, not inside, Jersey’s medical export business, but they help explain why officials have moved cautiously on the processing question too.

Is This Working Financially for Jersey?

Jersey’s medicinal cannabis industry turned a profit for the first time in 2025, generating more than £12 million in revenue against almost £50 million of total investment and employing around 70 people, according to a States Assembly report covered by Jersey Evening Post. Economic Development Minister Kirsten Morel called for renewed political “recommitment” to the sector, describing it as “high-value, low-footprint” in a follow-up report from Jersey Evening Post.

That’s a big milestone for an industry that started with a handful of repurposed greenhouses, though it still looks small next to finance, which drives roughly 38% of Jersey’s overall economy. Jersey’s own 2023-2026 Export Strategy named medical cannabis a “strong opportunity” for the island going forward, a sign that the government sees more room to grow this sector even as it works through the processing and public health questions still in front of it.

Frequently Asked Questions

• Watch: Inside LA’s Secret Black Market Weed Packaging Mecca
• Portugal Says Cannabis Export Certificates Now Take 12 Days. Operators Say Months
• Morocco Exports First Cannabis Medicine
• NECANN – New Jersey